Abstract Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ cancers, while Mel-
Introduction
Non-Hodgkin's lymphomas show a wide spectrum of morphology and variability in prognosis between different subtypes. Genetic abnormalities are not enough to explain the Electronic supplementary material The online version of this article (doi:10.1007/s00428-013-1428-y) contains supplementary material, which is available to authorized users. entire multistep lymphomagenesis process. Aberrant epigenetic changes, including DNA methylation, histone modifications, chromatin remodeling, and noncoding RNAs, also contribute to the development and progression of malignancy [1] [2] [3] .
Polycomb group (PcG) proteins are important regulators of lymphopoiesis that suppress gene expression through epigenetic modifications [4] . They form large multimeric complexes known as polycomb repressive complexes (PRCs), which bind to chromatin and control histone modifications. In mammals, there are two main PcG complexes: PRC1 and PRC2. PRC2 includes the enhancer of zeste homologue 2 (Ezh2), Eed, Suz12, RBBP4/7, and Jarid2 [5] . PRC1 includes several complexes that differ in their localization and function. So far, six subgroups have been identified and numbered (PRC1.1-1.6). All of them contain RING1 A and RING1 B enzymes, which ubiquitinate histone H2A at the lysine 119 residue [6] . Ezh2 is a histone H3 lysine 27 methyltransferase that generates H3K27me3, which is reported to be the binding site of PRC1, resulting in the ubiquitination of histones [7, 8] . This association with H3K27me3 was recently proven to be specific to PRC1.2 and PRC1.4 [6] . The interaction between PRC1 and PRC2 facilitates chromatin compaction and silencing of important tumor suppressors and genes involved in development, differentiation, adhesion, cell cycle progression, and proliferation. Both groups are important developmental regulators in both stem and cancer cells that help control the cell cycle, immortalization, and self-renewal of normal stem/progenitor cells [4, [9] [10] [11] .
Bmi-1/PCGF4 is a component of the PRC1.4 complex and was described as a proto-oncogene that induced lymphomas in mice. The upregulation of Bmi-1 was reported in a variety of cancers and sometimes correlated with a poor prognosis [6, [12] [13] [14] . Mel-18/PCGF2 is a component of the PRC1.2 complex and was previously described as a tumor suppressor that is expressed in the normal state and suppressed in neoplastic conditions in gastric, prostate, and breast cancers [15] [16] [17] . PRC1.2 and PRC1.4 complexes are formed, one with canonical PcG components (CBXs, PHCs, and SCMs) and one with RYBP or YAF2, in addition to Bmi-1/PCGF4 or Mel-18/PCGF2 [6] .
Ezh2 overexpression has been reported in solid organ cancers, including breast, prostate, and stomach cancers. It is associated with metastasis, poor prognosis, and treatment failure [18] [19] [20] . Somatic gain-of-function mutations in the SET domain of Ezh2, which result in increased histone methylation levels, were reported in follicular lymphomas (FL) and diffuse large B cell lymphoma (DLBCL). This is in contrast to the loss-of-function mutations reported in patients with myeloid malignancies, most commonly in those with myelodysplastic/myeloproliferative neoplasms and myelofibrosis [21] [22] [23] . However, much remains unknown about the expression profiles of PcG proteins and their significance in terms of the pathology of lymphoma, especially in T/NK cell lymphomas. This study investigated the expression patterns of Bmi-1, Ezh2, and Mel-18 in different subtypes of B and T/NK cell neoplasms and examined the possible correlation with Ki67 expression as a marker of tumor proliferation.
Materials and methods

Patient samples
Paraffin blocks of 197 lymphoma samples from the archives of the Department of Pathology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University were used for the present analyses. The demographic data of the patients and the locations of the neoplasms are summarized in Supplemental Table S1 . Reactive lymphoid hyperplasia (RLH; eight specimens), tonsil (five specimens), inflammatory non-neoplastic skin lesions (four specimens), and thymus (two specimens) were used as normal controls. Informed consent was obtained from all patients for the analysis of their tissue samples. This study was approved by the Institutional Review Board of the Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University and related hospitals, in accordance with the Declaration of Helsinki. The classification of the neoplasms was done according to the REAL/WHO classification. DLBCL cases were further divided into two groups, germinal center type (DLBCL-GCB) and non-germinal center type (DLBCL non-GCB), according to the Hans algorithm [24, 25] .
Cell culture
The cell lines and culture conditions are summarized in Supplemental Table S2 . Peripheral blood mononuclear cells (PBMCs) and CD4 + T cells from healthy donors were used as normal controls. Immunomagnetic isolation was done using EasySep® Human CD4 + T cell Enrichment Kit (#19052, Stemcell Technologies, Vancouver, BC, Canada). The Dynabeads® human T cell activator CD3/CD28 was used to activate and expand human T cells (Invitrogen, Oregon, USA).
Immunohistochemical staining
Paraffin blocks were retrieved, and new sections were used to ensure the quality of staining. Cases in which paraffin blocks were not available to make new sections were excluded. The following mouse monoclonal antibodies were used: Ezh2 (clone M18) [26, 27] , Bmi-1, and CD34 (Abcam, MA, USA), CD3, CD20, CD56, and MUM-1 (Novocastra, Newcastle upon Tyne, UK), CD4 and CD8 (Nichirei Biosciences Inc., Tokyo Japan), CD10, CD68, and CD138 (Dako, Glostrup, Denmark), BCL6 and rabbit anti-Mel-18 (Santa Cruz Biotechnologies Inc., Texas, USA), and anti-Ki67 (Novocastra, Newcastle upon Tyne, UK). Staining was done with a Leica BOND-MAX™ autostainer (Leica Biosysytems, Melbourne, VIC, Australia). Both the intensity of staining and percentage of positive tumor cells were evaluated in ten high-power fields by three investigators. A high Ki67 labeling index was defined as nuclear staining of ≥20 % of tumor cells. Positivity was defined as ≥25 % nuclear staining of tumor cells, in accordance with previous reports [14, 20] . Positive cases were further scored as (+), (++), and (+++) based on the intensity of the staining, which was judged by comparing it to internal control cells. Endothelial cells or adjacent normal/reactive lymphoid tissue served as an internal control for Bmi-1. For Ezh2, an adjacent germinal center in nodal and duodenal specimens, or the basal epithelial layer in the case of skin and mucous membrane specimens, was used as the internal control. For Mel-18, endothelial cells were used as the internal control. A control slide of either RLH or tonsil was also included in each staining run. For every case, the neoplastic nature of the stained cells was confirmed by its morphology and by using a selection from a panel of markers (including CD20, CD138, CD10, CD3, CD4, CD7, CD8, CD56, cyclin D1, and BCL2). A combination of each marker (Ezh2, Bmi-1, or Ki67) with B and T/NK cell markers (CD20, CD3, CD56, and CD138) was done in normal lymphoid tissue and selected cases of lymphoma.
Double fluorescent immunocytochemical and immunohistochemical staining
The cells were washed with PBS then processed via cytospin (10 5 per slide) and fixed in cold acetone. Blocking was done by incubation in 5 % skim milk for 5 h at room temperature. After washing, the cells were treated with a mixture of two primary antibodies for 3 to 5 h at room temperature. Washing was repeated, and then samples were incubated with a mixture of anti-mouse and anti-rabbit IgG for 2 to 3 h at room temperature. The primary antibodies included rabbit monoclonal anti-Ezh2 (Cell Signaling, Beverly, MA, USA) and mouse monoclonal anti-Bmi-1 (Abcam, MA, USA). The secondary antibodies were anti-mouse IgG Alexa Flour 555 and anti-rabbit IgG Alexa Flour 488 (Invitrogen, Oregon, USA). Slides were mounted with SlowFade® Gold Antifade Reagent with DAPI (Invitrogen, Oregon, USA) and examined with a conventional immunofluorescence microscope (IX71, Olympus, Tokyo, Japan). The following combinations were used: Ezh2 with Bmi-1, Ezh2 with Ki67, and Bmi-1 with Ki67.
Western blotting analysis
The Western blot analyses were performed as described previously [28] . Rabbit anti-Ezh2, mouse anti-Bmi-1, rabbit anti-Mel-18 (Santa Cruz Biotechnologies Inc., Texas, USA) and mouse anti-beta-actin (Sigma Aldrich, St. Louis, USA) antibodies and HRP-labeled anti-rabbit or anti-mouse antibodies (NA9340V GE and NA9310V, respectively, GE Healthcare, Little Chalfont, Buckinghamshire, UK) were used for the analyses.
Statistical analysis
All statistical analyses were done with the SPSS version 11.5 software program. Pearson's chi-squared test and oneway analysis of variance (ANOVA) with the Bonferroni correction were used to compare the different lymphoma subtypes. Spearman's and Pearson's coefficients were used for the correlation analyses of Bmi-1, Ezh2, and Ki67.
Results
Expression of Bmi-1 and Ezh2 in normal lymphoid tissues
In RLH, the expression of Bmi-1 and Ezh2 was mutually exclusive. Bmi-1 was mainly expressed in the mantle zone, while Ezh2 was expressed in the germinal center; centroblasts showed stronger staining than centrocytes. Fig. S1 ). The cutaneous CD3 + T cells were Ezh2−. In the normal thymus, the cortical thymocytes were mostly Ezh2+/Bmi-1−. In the medulla, the pattern was reversed; the dominant population of CD3 + cells was Ezh2−/Bmi-1+ (Table 1 ; Fig. S2 ). The staining intensity for Bmi-1 in both RLH and the thymus was generally weak to moderate ( Table 1 ). The normal stratified squamous epithelium covering the tonsils showed nuclear staining for Ezh2, mostly in the basal layers, while Bmi-1 staining generally showed low expression (Fig. S3 ).
High expression of Bmi-1 and Ezh2 in Hodgkin's lymphoma and B cell neoplasms In Hodgkin's lymphomas, the coexpression of both Bmi-1 and Ezh2 was found in the tumor cells in nine out of ten cases (90 %), but was not found in the reactive background cells (Table 1 ). In B cell neoplasms, the overall expression of Bmi-1 was 84.4 %. The staining intensity was generally moderate (72 cases) to strong (9 cases). Bmi-1 expression was found in all subtypes, ranging from 58.3 % in Burkitt's 
Positivity includes (−), (+), (++), and (+++). Data from RLH and thymus are based on cell count
HD Hodgkin lymphoma, BL Burkitt's lymphoma, DLBCL-GCB diffuse large cell B cell lymphoma germinal center type, DLBCL non-GCB diffuse large B cell lymphoma non-germinal center type, FLG3 follicular lymphoma grade 3, FLG1-2 follicular lymphoma grade 1-2, MCL mantle cell lymphoma, CLL/SLL chronic lymphocytic leukemia/small lymphocytic lymphoma, PCM plasma cell myeloma, PC plasmacytoma, LPL lymphoplasmacytic lymphoma, MALT mucosa-associated lymphoid tissue, T-LBL T cell lymphoblastic lymphoma, ATLL adult T cell leukemia/lymphoma, ALCL anaplastic large cell lymphoma, PTCL peripheral T cell lymphoma, NK/T natural killer/T cell lymphoma, AITL angioimmunoblastic T cell lymphoma, CTCL cutaneous T cell lymphoma, RLH reactive lymphoid hyperplasia lymphoma (BL) to 100 % in four subtypes: Mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mucosa-associated lymphoid tissue (MALT) lymphoma, and plasmacytoma (PC) ( Fig. 1 ). The expression in BL, DLBCL-GCB, and FLG3 showed significant differences compared to the germinal center dark zone (Table 1 ; χ 2 =15.221, P=0.002), and the percentage of positive tumor cells was above 70 % in ten cases. No significant difference was found between FLG1-2 and follicular lymphoma grade 3 (FLG3) in either the percentage or intensity of staining. In addition, no difference was noted between the DLBCL-GCB and DLBCL non-GCB subtypes.
The overall expression of Ezh2 in B cell neoplasms was 56.9 % ( Table 1 ). The expression varied among the different subtypes. The highest percentage of positivity Fig. 1 Immunohistochemical staining of Bmi-1 and Ezh2 in RLH and B cell neoplasms. a Bmi-1 expression was detected mainly in the mantle zone (MZ), while the germinal center (GC) was negative. b Ezh2 expression was detected in the GC, while the MZ was negative (insets show a higher magnification of the GC). c, d DLBCL-GCB type was strongly positive for Bmi-1 and Ezh2, respectively. e, f FLG3 was strongly positive for Bmi-1 and Ezh2, respectively. g, h PCM was strongly positive for Bmi-1 and negative for Ezh2, respectively (a, b magnification ×200, inset ×400 and c to h magnification ×400) was found in BL, FLG3, and DLBCL (100, 87.5, and 85.7 %, respectively). The percentage of positive tumor cells was generally >80 % in the three entities. FLG3 showed 87.5 % positivity versus 57.8 % in FLG1-2. The strongest staining intensity was seen in DLBCL-GCB, in which 8 out of 14 cases (57.1 %) showed stronger staining intensity than the germinal center dark zone, while the staining in FLG3 was comparable to the latter (Table 1 ; Fig. 1 High expression of Bmi-1 and Ezh2 in T and NK/T cell non-Hodgkin's lymphomas
The overall expression of Bmi-1 was 84.6 % in T and T/NK cell lymphomas. Bmi-1 was expressed in all subtypes, ranging from 66.7 % in adult T cell leukemia/lymphoma (ATLL) and up to 100 % in three subtypes: angioimmunoblastic T cell lymphoma (AITL), cutaneous T cell lymphoma (CTCL), and anaplastic large cell lymphoma (ALCL) ( Ezh2 expression was observed in all T and T/NK cell lymphoma subtypes, ranging from 66.7 % in AITL to 100 % in CTCL (Table 1) . A moderate staining intensity in these neoplasms was noted, which was in contrast to almost a complete lack of expression of Ezh2 in normal CD3 + , CD4 + , and CD56 + cells in RLH and skin (Figs. 2, S1 , and S2). Among the positive cases, the highest percentage of positive tumor cells was in T cell lymphoblastic lymphoma (T-LBL) (90 %) and the lowest was in CTCL (40 %). In mature T and T/NK cell lymphomas, significant overexpression of both proteins compared to interfollicular, follicular, and cutaneous CD3 + T cells, as well as CD56 + NK cells, was detected (χ 2 =13.075, P=0.007 for Bmi-1 and χ 2 =38.942, P=0.000 for Ezh2).
Significant differences in Ezh2, but not Bmi-1, expression between high-grade and low-grade B cell neoplasms High expression levels of Ezh2 were found mainly in the aggressive variants of B cell neoplasms, while Bmi-1 was highly expressed in all subtypes with no noticeable difference between them (Fig. 3a) . The chi-squared test for Ezh2 showed a significant difference between the subgroups of B cell lymphomas (χ 2 =37.561, P=0.000), and a one-way ANOVA with Bonferroni correction revealed that there were significant differences between the aggressive subtypes (BL, DLBCL-GCB, DLBCL non-GCB, and FLG3) and the indolent subtypes (FLG1-2, PC, PCM, LPL, CLL/SLL, and MALT lymphoma) (mean difference=1.06-2.31, P=0.000-0.030). This difference corresponded to the differences in the Ki67 index (mean difference=0.56-1.00, P=0.000-0.018) among these subtypes ( Table 2 ). The chisquared test for Bmi-1 showed a difference in expression between the subtypes of B cell lymphomas (χ 2 =99.257, P= 0.000). However, a one-way ANOVA with Bonferroni correction detected a single statistically significant difference between BL and MALT lymphoma (mean difference= −1.38, P=0.004) ( Table 2) . No statistically significant differences were between the subtypes of T/NK cell lymphomas with regard to the expression of Bmi-1, Ezh2, and Ki67 ( Fig. 3b ; Supplemental Table S3 ).
Ezh2 expression correlated with the proliferative activity
The Ki67 labeling index showed a strong positive correlation with Ezh2 expression in B cell neoplasms (correlation coefficient (Co)=0.983, P=0.000) and a considerable correlation in T and T/NK cell lymphomas (Co=0.629, P= 0.000). This correlation was not detected in the case of (Fig. 4a) . Fluorescent immunohistochemical staining of Ezh2 and Ki67 in DLBCL showed that almost all cells strongly coexpressed Ezh2 and Ki67. A low Ki67 proliferation index was observed in MALT lymphoma, which closely correlated with a low expression of Ezh2 (Fig. 4b, white  arrowhead) . A few cells were stained weakly for Ki67 and Ezh2 (yellow arrowhead). Some cells showed intracellular colocalization of Ezh2 and Ki67 (red arrowhead). Fluorescent immunohistochemical staining revealed that the expression of Ezh2 closely correlated with that of Ki67 in almost all cells in B cell lymphoma, in accordance with the correlation analysis (Fig. 4a, b) . Normal stratified squamous epithelium covering the tonsils showed nuclear and cytoplasmic staining in both the basal and superficial layers (Fig. S3) .
Expression of Mel-18 in RLH and malignant lymphomas
Mel-18 was expressed in 14.7 % of B cell neoplasms. DLBCL-GCB, DLBCL non-GCB, FLG1-2, PCM, and PC all showed weak expression in 16.7 % of cases. MALT lymphoma showed weak expression in 10 % of cases. In T/NK cell neoplasms, Mel-18 was expressed in 20 % of cases. Both NK/T lymphoma and ALCL expressed Mel-18 in 33.4 % of cases. T-LBL and ATLL showed expression in 16.7 % of cases, while PTCL was negative in all cases. The staining intensity was typically weak, and the percentage of positive tumor cells was generally below 40 % in the positive cases. Mel-18 was expressed weakly in 11 out of 64 non-Hodgkin's lymphomas (Table 3 ; Fig. 5 ). Coexpression of Mel-18 and Bmi-1 was observed in ten lymphoma cases. It is worth mentioning that one case of DLBCL non-GCB showed moderate staining for Mel-18 in 80 % of tumor cells, and this case was Bmi-1 negative.
Expression of Ezh2, Bmi-1, and Mel-18 in hematopoietic cell lines
Normal resting PBMCs and CD4 + cells were negative for Ezh2 and Mel-18, while the expression of Bmi-1 varied a little; a faint signal was observed in PBMCs#1 and normal NK cells. The expression of the three proteins was not stable in PBMCs; stimulation of normal T cells with CD3/CD28 immunobeads induced a weak expression of all three proteins (Fig. 6c) . Human mesenchymal stem cells showed a strong expression of both Bmi-1 and Ezh2 and a weak expression of Mel-18. Lymphoma cell lines showed higher levels of both Bmi-1 and Ezh2 proteins compared to normal PBMCs. Mel-18 showed Fig. 2 Immunohistochemical staining of Bmi-1 and Ezh2 in T and NK cell lymphomas (a) and ATLL (b) was strongly positive for Bmi-1 and Ezh2, respectively. c, d NK/T lymphoma was strongly positive for Bmi-1 and Ezh2, respectively. e, f T-LBL was strongly positive for Bmi-1 and Ezh2, respectively (magnification ×400) weak or no expression in B cell lymphoma cell lines and T/NK lymphoma/leukemia cells compared to the high expression of Bmi-1. HTLV-I immortalized cell lines (IWA1, MT4, and MT2) showed enhanced expression of Bmi-1, Mel-18, and Ezh2 proteins compared to PBMCs and normal CD4 + cells. The ratio of Bmi-1/Mel-18 was comparable in normal PBMCs and HTLV-I immortalized cell lines; on the other hand, this ratio noticeably increased in malignant lymphoma cell lines (Fig. 6a, b) .
Immunofluorescent staining showed that normal resting PBMCs were negative for Ezh2 and a small population was weakly positive for Bmi-1. Immunofluorescent staining of several B and T/NK lymphoma cell lines confirmed the higher expression levels of both proteins compared to those in normal PBMCs (Fig. S4) .
Discussion
The expression profiles of Bmi-1 and Ezh2 in normal lymphoid tissues were mutually exclusive. Bmi-1 was expressed in the resting cells of the mantle zone, interfollicular T zone, and a small percentage of plasma cells, while Ezh2 was expressed in the proliferating cells of the germinal center. In the thymus, Ezh2 expression predominated in the cortex, while Bmi-1 predominated in the differentiated cells of the medulla. This is consistent with the findings of previous reports [29] [30] [31] [32] . Mel-18 expression in RLH was generally low, which is also consistent with previous reports [33] .
The present study showed that Bmi-1 is highly expressed in all subtypes of both B and T cell lymphomas, including the indolent types: MALT lymphoma, PC, PCM, LPL, and CLL/SLL. Bmi-1 was previously reported to be preferentially 
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Reactive lymphoid hyperplasia Fig. 3 expressed in aggressive B cell lymphoma (DLBCL and BL) but not in indolent subtypes (FL and CLL/SLL) [34] . In the case of FL, the present study showed that Bmi-1 expression is highly heterogeneous and dependent on each patient specimen; this might be due to differences in the patient populations (Table 1) . No significant differences in the expression level of Bmi-1 were found between different grades of FL in the present study, suggesting that the expression of Bmi-1 does not contribute to the progression from low-grade to high-grade FL. Bmi-1 was reported to be one of the genes showing the signature of activated B cell (ABC) type DLBCL, and could be used to distinguish it from the GCB type by a cDNA microarray analysis, and was, therefore, considered to be associated with a poor prognosis [35] . Later reports based on the immunohistochemical analyses showed that Bmi-1 expression was not restricted to the ABC type [14] . The present study showed that both GCB and non-GCB types expressed Bmi-1 with no significant difference noted between the subtypes (Tables 1 and 2 ), suggesting that the earlier differences might have been due to the differences between protein and mRNA expression since they are not always consistent. In this study, enhanced expression of Bmi-1 compared to the normal counterpart samples was found in some subtypes of lymphomas: BL, DLBCL-GCB, FLG1-3, PC, PCM, and T cell lymphomas (P=0.002-0.033). This is consistent with reports that Bmi-1 transgenic mice developed lymphoma and that Bmi-1 is a negative regulator of the INK4a-ARF locus, which encodes tumor suppressor proteins p16
Ink4a
, p19
Arf , and p15 Ink4b [13, 36] . Meanwhile, Ezh2 showed a different expression profile in malignant lymphomas. The present study showed that Ezh2 expression was significantly stronger in the aggressive types of B cell neoplasms (BL, DLBCL, and FLG3) than the indolent subtypes (FLG1-2, SLL, LPL, PC, PCM, and MALT lymphoma) (P=0.000-0.030) ( Table 2 ). The Ezh2 positivity in FLG3 was higher than that in FLG1-2. In T/NK cell lymphomas, Ezh2 showed high expression compared to the lack of expression observed in normal counterpart samples (χ 2 =38.942, P=0.000). However, no significant difference between subtypes was noted, which could be explained by the fact that most T/NK cell lymphomas were aggressive with a high Ki67 proliferation index (Table 1 ). This was supported by the strong positive correlation between Ki67 and the Ezh2 expression in B cell lymphoma (Co=0.983, P=0.000) and the considerable correlation in T cell lymphoma (Co=0.629, P=0.000) (Fig. 4a) . This is consistent with previous reports that Ezh2 overexpression is associated with increased proliferation, metastasis, and poor prognosis in breast, prostate, and stomach cancers [18] [19] [20] . These findings suggest that Ezh2 overexpression is also associated with the proliferation and aggressiveness in lymphoma.
It has been reported that Bmi-1 and other members of PRC1 function downstream of PRC2 [7, 8] . However, the present study showed that there are different expression patterns of Bmi-1 and Ezh2. These proteins do not always colocalize in RLH and malignant lymphomas indicating that, at least in some situations, they function independently. This is supported by evidence that there are genes targeted by PRC2 that lack the product of PRC1 catalysis (H2AK119ub) and genes targeted by PRC1 in the absence of PRC2 [37, 38] .
McCabe et al. reported that GSK126 is a potent and highly selective inhibitor of Ezh2 methyltransferase activity that decreases the global H3K27me3 level and induces pharmacological inhibition of proliferation in the Ezh2 mutant lymphoma. GSK126 also reduces H3K27me3 levels in wild-type DLBCL cell lines [39] . In view of the low expression of Ezh2 in normal resting populations, selective pharmacological intervention to inhibit Ezh2 activity in both wild-type and mutant lymphomas is a promising approach that warrants further research. Mel-18 expression was previously reported in several normal adult tissues [15] [16] [17] . In RLH, we found that few cells expressed Mel-18 with moderate intensity, while some populations expressed Bmi-1 with weak to moderate intensity, especially in the mantle zone. In B and T/NK cell neoplasms, Bmi-1 expression was found in 158 out of 187 (84.5 %) of cases, and the staining intensity was mostly moderate (109 cases) to strong (26 cases), while Mel-18 was expressed weakly in 11 out of 64 cases (17.1 %) of B and T/NK cell neoplasms (Tables 1 and 3) . The Western blot analysis revealed that both B and T/NK cell lymphoma cell lines showed weak or no expression of Mel-18, in contrast to their moderate/strong expression of Bmi-1, while normal PBMCs were negative for Mel-18 and negative/faintly positive for Bmi-1 (Fig. 6) . The ratio of Bmi-1/Mel-18 (PRC1.4/PRC1.2) was comparable in normal PBMCs and HTLV-I immortalized cell lines and increased noticeably in malignant lymphoma cell lines. Together, these data suggest that the regulation of PRC1 in normal lymphoid tissue is in favor of PRC1.4, rather than PRC1.2, and that the difference increases with the development of malignancy. Only PRC1.2 and PRC1.4 complexes have been shown to accumulate in H3K27me3-rich regions; they induce chromatin compaction and gene silencing in different targets and are suggested to play a central role in PRC1 function [6] . The altered expression state may induce changes in the downstream gene targeting and expression in lymphomas.
In conclusion, B and T/NK cell neoplasms show high expression of both Bmi-1 and Ezh2 while maintaining low expression of Mel-18. The regulation of PRC1.2 and PRC1.4 shifts more towards PRC1.4 dominance in the neoplastic state. The coexpression of Bmi-1 and Ezh2 is a characteristic of the aggressive variants of these lymphomas. Ezh2 correlates with tumor proliferation and can be used to distinguish proliferative/aggressive lymphoma variants from indolent ones and normal resting cell populations. A detailed understanding of the precise role(s) of these proteins in lymphomagenesis is still lacking. However, correlation between the expression status of Ezh2 and the Bmi-1/Mel-18 ratio with the patients' prognosis may provide a useful method for the pathological evaluation of lymphomas in the future. nical support. This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (T.O.) (#22590312). Fig. 6 Results of the Western blot analyses of Bmi-1, Ezh2, and Mel-18 expression in malignant lymphoma cell lines and normal control cells. a Both Bmi-1 and Ezh2 were expressed in most B cell lymphoma lines; however, Ezh2 showed a stronger signal in the more aggressive lymphoma lines. Mel-18 was negative in most B cell lines. b Both Bmi-1 and Ezh2 were expressed in most T cell lymphoma lines. Mel-18 was weakly/faintly positive in ATLL leukemic cell lines (ED40515 and ATL55T). This was in contrast to HTLV-I immortalized cell lines (IWA1, MT4, and MT2), which showed an expression level comparable to that of Bmi-1. c Normal PBMCs#1 and normal NK cells showed a faint signal for Bmi-1, while they were negative for Ezh2 and Mel-18. Activated T cells showed a faint expression of all three proteins. PBMCs#1 to #4 peripheral blood mononuclear cells from four healthy individuals, Activate T T cells activated with a CD3/CD28 cell expander, Norm NK normal natural killer cells
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